BioNTech’s Strategic Overhaul Faces Dual Test in May

Investors are bracing for a pivotal fortnight at BioNTech SE, with a first-quarter earnings report and a consequential shareholder meeting set to define the company’s ambitious transformation. The German biotech’s shares have already reacted, closing at 92.30 EUR on Tuesday, a gain of roughly ten percent over the prior week. Trading volume hit double the average, signaling focused buying interest rather than mere technical moves.

The immediate financial picture remains challenging. For the full 2026 fiscal year, BioNTech anticipates revenue of between 2.0 and 2.3 billion EUR, a decline of approximately 25 percent from the prior year as its COVID-19 vaccine business winds down. The Q1 report on May 5 will offer the first concrete look at this trajectory following a net loss of 1.14 billion EUR for the 2025 fiscal year. The company has stressed it does not expect product revenue from its oncology segment in 2026.

Yet, the market appears to be looking beyond near-term headwinds. The stock, recently trading around 94.65 EUR, now sits more than 23 percent above its level from a month ago and has climbed about 27 percent from its March 52-week low. It is also trading above its 200-day moving average of roughly 88 EUR, though it remains about ten percent below its 52-week high of 105.90 EUR.

A formidable war chest underpins this strategic patience. BioNTech held approximately 17.2 billion EUR in cash and cash equivalents at the end of 2025. This reserve is intended to fund the costly clinical development pipeline through to potential product approvals, buying the company critical time for its reinvention as a focused oncology firm.

The most imminent catalyst in that pipeline is a planned Biologics License Application (BLA) submission to the U.S. FDA for the antibody-drug conjugate Trastuzumab Pamirtecan (BNT323/DB-1303) in endometrial cancer. The candidate, which already holds FDA Fast-Track and Breakthrough Therapy designations, demonstrated an objective response rate of nearly 48 percent in Phase 2 trials, exceeding 70 percent in the HER2 IHC 3+ subgroup. Partner DualityBio has already submitted a corresponding application to China’s NMPA for HER2-positive breast cancer, which was accepted for review in April 2026.

Should investors sell immediately? Or is it worth buying BioNTech?

Beyond this key asset, BioNTech’s clinical engine is accelerating. The company aims to increase the number of ongoing Phase 3 trials to 15 this year, adding six new studies. It also anticipates seven late-stage data readouts across various cancer indications and is currently conducting 16 clinical trials in lung cancer alone, including four ongoing Phase 3 studies.

The formal architecture for this new era will be debated at the virtual Annual General Meeting on May 15. Shareholders will vote on expanding the Supervisory Board from six to eight members, with the new seats reserved for experts in oncology and clinical development. They will also be asked to approve a domination and profit transfer agreement with subsidiary BioNTech Discovery GmbH, a move to create a tax group for offsetting losses at the parent level—a critical financial maneuver given recent results. A new authorized capital 2026 of up to approximately 129.5 million EUR, equivalent to 50 percent of the current share capital, is also on the agenda.

These governance changes coincide with a looming leadership transition. Co-founders Ugur Sahin and Özlem Türeci are set to depart BioNTech by the end of 2026, and the Supervisory Board has initiated a search for their successors.

The median price target among nine analysts stands at 130 USD, reflecting confidence that the company’s substantial resources can bridge the gap to its oncology future. How effectively BioNTech is navigating that journey will become clearer when management details its progress on the earnings call scheduled for May 5 at 14:00 CET.